Our data show that adapter-tethered EGFR and ERBB2 fusions are capable of sustaining cancer cell growth and proliferation and, importantly, are sensitive to inhibition with EGFR and/or HER2 inhibitors. The gene discussed is EGFR; the disease is cancer.